Oligomerix is an early-stage biotech company founded in November 2006 with the primary goal of developing a proprietary platform technology for drug discovery and biomarker development for neurodegenerative diseases with a focus on Alzheimer’s disease (AD). This program seeks to enable the development of a disease modifying therapeutic (DMT) for AD using a small molecule approach targeting tau self-association into toxic oligomers. In vivo proof-of-concept was shown in preventive studies in htau and JNPL3 mice that model tau aggregation in both AD and frontotemporal dementia. The lead is in preclinical development and work on a translational biomarker is in progress. The Company has built a sound business model around its core technologies, a strong intellectual property position and a highly experienced management team. The Company’s validated small molecule lead compounds and companion biomarker assays will enable strategic partners to accelerate and de-risk clinical development.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
First-in-class, best-in-class small molecule inhibitor of tau self-association for AD
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):